Figure 4.

Overlay of pharmacokinetic (PK) profiles as predicted a priori using the physiologically‐based pharmacokinetic (PBPK) model with observed data from the first‐in‐human trial. Bamlanivimab serum concentrations from cohorts of patients receiving 700, 2,800, or 7,000 mg of bamlanivimab. Red data points are the observed clinical data from each of the respective three cohorts. The grey shaded area represents the 90% prediction interval from PBPK modeling with the black dotted line representing the median.